Search results for "Systemic chemotherapy."

showing 10 items of 14 documents

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

2018

Background: At present, there is uncertainty on the best systemic treatment in first-line setting for RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. Indeed, several chemotherapy and biologics combinations showed an improvement on survival. We performed a systematic review with a pair-wise and bayesan meta-analysis to rank the best strategy for these patients. Methods: A systematic literature search through March 2017 was performed to evaluate the association between several treatment combinations and overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity rate (TR) in RAS WT mCRC patients. Data were extracted from studies and pooled…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentBayesian probabilitySidednessDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientMeta-analysiSystemic chemotherapyNeoplasm MetastasisRAS wild-typeChemotherapyVbusiness.industryMetastatic colorectal cancerWild typeBayes TheoremHematologymedicine.diseaseNeoadjuvant TherapyFirst line treatmentMeta-analysisSafety profileGenes ras030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisSystemic chemotherapy.Colorectal Neoplasmsbusiness
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease

1992

SummaryThis paper is an up-dated review of the role of systemic chemotherapy in the management of recurrent and/or metastatic head and neck carcinoma.

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyAntineoplastic AgentsDiseaseHead neck cancer03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Head and neckHead and neck carcinomaPharmacologyChemotherapybusiness.industrySystemic chemotherapyHead and neck cancerAdvanced stagemedicine.diseaseSurgeryInfectious DiseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisRadiologyNeoplasm Recurrence Localbusiness
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence doe…

2015

It is still uncertain if targeted therapy-based regimens in advanced gastric cancer actually produce survival benefit. To shed light on this important question, we performed a systematic review and meta-analyses on each relevant targeted-pathway. By searching literature databases and proceedings of major cancer meetings in the time-frame 2005–2014, 22 randomized clinical trials exploring targeted therapy for a total of 7022 advanced gastric cancer patients were selected and included in the final analysis. Benefit was demonstrated for antiangiogenic agents in terms of overall survival (HR 0.759; 95%CI 0.655–0.880; p < 0.001). Conversely no benefit was found for EGFR pathway (HR 1.077; 95%…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentAngiogenesis InhibitorsBioinformaticsTargeted therapylaw.inventionTargeted therapyRandomized controlled trialTargeted pathwayStomach NeoplasmlawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMeta-analysiMolecular Targeted TherapySystemic chemotherapySurvival analysisRandomized Controlled Trials as TopicPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerAdvanced gastric cancermedicine.diseaseSurvival AnalysisErbB ReceptorsAngiogenesiPooled analysisOncologyTolerabilityMeta-analysisClinical StudyMolecular MedicineReceptor Epidermal Growth FactorSurvival AnalysiRandomized clinical trialbusinessGastric cancerAngiogenesis InhibitorHuman
researchProduct

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort

2020

PURPOSE The HIT-2000-BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local radiotherapy. PATIENTS AND METHODS From 2001-2011, 87 patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for nonresponse or progression. After 2006, local radiotherapy was introduced for nonresponders or patients with classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA). DNA methylation profiles of infantile sonic hedgehog-activated medulloblastoma (SHH-INF) were subdivided i…

OncologyMaleCancer ResearchMedizinradiotherapy [Medulloblastoma]Neuropsychological Testsadverse effects [Cranial Irradiation]Craniospinal Irradiation0302 clinical medicinemortality [Cerebellar Neoplasms]drug therapy [Medulloblastoma]Early childhoodProspective Studiesddc:618Systemic chemotherapyCerebellar Neoplasms / mortality3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolMedulloblastoma / radiotherapyFemalemortality [Medulloblastoma]medicine.medical_specialtyCerebellar Neoplasms / drug therapyCerebellar Neoplasms / radiotherapyMEDLINEMedulloblastoma / drug therapyadministration & dosage [Methotrexate]03 medical and health sciencesInternal medicinedrug therapy [Cerebellar Neoplasms]medicineHumansddc:610Cerebellar NeoplasmsMedulloblastomaCranial Irradiation / adverse effectsbusiness.industryEditorialsInfantMethotrexate / administration & dosageDNA Methylationmedicine.diseaseClinical trialMethotrexateMedulloblastoma / mortalityradiotherapy [Cerebellar Neoplasms]Cranial IrradiationbusinessValidation cohort030217 neurology & neurosurgeryMedulloblastoma
researchProduct

Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases…

2020

Highlights • Integration of PIPAC to systemic chemotherapy can have good tolerance profile. • Repeated biopsies performed during PIPAC allowed therapy-response monitoring. • Analysis of biopsies performed during PIPAC allowed tailoring of chemotherapy. • Integration of PIPAC to systemic chemotherapy can permit good quality of life.

Oncologymedicine.medical_specialtymedicine.medical_treatmentCase ReportPancreatic ductal adenocarcinoma03 medical and health sciences0302 clinical medicinePharmacokineticsQuality of lifeInternal medicinemedicineMultimodal treatmentAdverse effectChemotherapyPressurized intraperitoneal aerosol chemotherapy (PIPAC)CarcinomatosisSystemic chemotherapybusiness.industryStandard treatmentfungifood and beveragesPeritoneal metastases030220 oncology & carcinogenesisDrug delivery030211 gastroenterology & hepatologySurgerybusinessInternational Journal of Surgery Case Reports
researchProduct

Primary multifocal anaplastic large cell lymphoma with eyelid involvement: a case report

2019

ABSTRACT Ocular adnexal involvement in CD30+ lymphoproliferative disorders is rare. We report the case of a 73-year-old woman with a relapsing primary cutaneous anaplastic large cell lymphoma on her eyelid. A systemic extension study excluded extracutaneous involvement. Systemic chemotherapy resulted in an optimal response, with complete regression of the cutaneous lesions. There has been no recurrence during the 2 years of follow-up. RESUMO O acometimento ocular adicional nos distúrbios linfoproliferativos CD30+ é raro. Relatamos o caso de uma mulher de 73 anos com linfoma de grandes células anaplásicas primárias recidivantes em sua pálpebra. A avaliação sistêmica excluiu envolvimento extr…

Pathologymedicine.medical_specialtyCD30Neoplasias palpebraisLymphoproliferative disordersPrimary cutaneous anaplastic large cell lymphomalcsh:OphthalmologyComplete regressionmedicineLinfoma anaplásico cutâneo primário de células grandesAnaplastic large-cell lymphomaLymphoma primary cutaneous anaplastic large cellCase reportsRelatos de casosSystemic chemotherapybusiness.industryGeneral MedicineLymphoma T-cell cutaneousEyelid Neoplasmmedicine.diseaseOphthalmologymedicine.anatomical_structurelcsh:RE1-994Linfoma cutâneo de células TEyelidbusinessEyelid neoplasms
researchProduct

Primary Mucinous Adenocarcinoma of the Urinary Bladder with Signet-Ring Cells: Description of an Uncommon Case and Critical Points in Its Management

2016

We present an uncommon case of mucinous adenocarcinoma of the bladder (MAB) with signet-ring cells extensively infiltrating prostate gland and pelvic/retroperitoneal lymph node stations and not responsive to usual systemic chemotherapy regimens. This case highlights the important features of MAB including the pattern of tumor spread, the tendency for initial misdiagnosis, and the importance of immunohistochemical study in order to define its primary origin from the bladder and choose the most appropriate treatment since the beginning.

Pathologymedicine.medical_specialtyUrinary bladderSignet ring cellSystemic chemotherapybusiness.industryRetroperitoneal Lymph Node030232 urology & nephrologyCase ReportGeneral Medicinemedicine.diseaselcsh:Diseases of the genitourinary system. Urologylcsh:RC870-92303 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesismedicineAdenocarcinomaImmunohistochemistryProstate glandbusinessCase Reports in Urology
researchProduct

Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcino…

2020

Background: Systemic chemotherapy for pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CC) with peritoneal metastases (PM) is affected by several pharmacological shortcomings and low clinical efficacy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is expected to maximize exposure of peritoneal nodules to antiblastic agents. This study aims to evaluate safety and efficacy of PIPAC for PM of PDAC and CC origin. Methods: This is a retrospective analysis of consecutive PDAC and CC cases with PM treated with PIPAC at two European referral centers for peritoneal disease. We prospectively recorded from August 2016 to May 2019 demographic, clinical, surgical, and oncological data…

Peritoneal metastasismedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEpancreatic cancerPIPACcarcinomatosislcsh:RC254-282Pancreatic cancerMedicineDoxorubicincarcinomatosiOriginal ResearchCisplatinChemotherapybusiness.industrySystemic chemotherapyperitoneal metastaseaerosol chemotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesOxaliplatinperitoneal metastasesOncologyCancer researchlocoregional chemotherapyAdenocarcinomaPIPAC.businesscholangiocarcinomamedicine.drugTherapeutic Advances in Medical Oncology
researchProduct